{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-24-000105","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.913398+00:00","generated_at":"2026-05-31T14:24:40.651471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook","bullets":["Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.","GAAP diluted EPS $0.30; adjusted diluted EPS $0.93.","Raised full-year 2024 revenue and adjusted diluted EPS guidance.","Franco Poletti named President of Cardiopulmonary Business Unit, effective August 1, 2024.","Plans to pursue CMS coverage for VNS Therapy in RECOVER patient population; reducing 2025 investment in difficult-to-treat depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-24-000105","json":"https://secwatch.observer/filing/0001639691-24-000105.json","markdown":"https://secwatch.observer/filing/0001639691-24-000105.md","text":"https://secwatch.observer/filing/0001639691-24-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000105/0001639691-24-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969124000105/livn-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:24:40.651471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}